DK2714006T3 - Intranasale bioadhæsive testosterongelformuleringer og anvendelse deraf til behandling af mandlig hypogonadisme - Google Patents

Intranasale bioadhæsive testosterongelformuleringer og anvendelse deraf til behandling af mandlig hypogonadisme Download PDF

Info

Publication number
DK2714006T3
DK2714006T3 DK12748245.3T DK12748245T DK2714006T3 DK 2714006 T3 DK2714006 T3 DK 2714006T3 DK 12748245 T DK12748245 T DK 12748245T DK 2714006 T3 DK2714006 T3 DK 2714006T3
Authority
DK
Denmark
Prior art keywords
treatment
gel formulations
testosterone gel
male hypogonadism
bioadhesive
Prior art date
Application number
DK12748245.3T
Other languages
Danish (da)
English (en)
Inventor
Wayne Kreppner
Siobhan Fogarty
Werner Oberegger
Paul José Pierre Marie MAES
Original Assignee
Acerus Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerus Biopharma Inc filed Critical Acerus Biopharma Inc
Application granted granted Critical
Publication of DK2714006T3 publication Critical patent/DK2714006T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK12748245.3T 2011-05-15 2012-05-15 Intranasale bioadhæsive testosterongelformuleringer og anvendelse deraf til behandling af mandlig hypogonadisme DK2714006T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486324P 2011-05-15 2011-05-15
US201161486634P 2011-05-16 2011-05-16
PCT/IB2012/001112 WO2012156820A1 (en) 2011-05-15 2012-05-15 Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism

Publications (1)

Publication Number Publication Date
DK2714006T3 true DK2714006T3 (da) 2021-03-15

Family

ID=46579248

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12748245.3T DK2714006T3 (da) 2011-05-15 2012-05-15 Intranasale bioadhæsive testosterongelformuleringer og anvendelse deraf til behandling af mandlig hypogonadisme

Country Status (16)

Country Link
EP (3) EP3977982A1 (cg-RX-API-DMAC7.html)
JP (9) JP6152092B2 (cg-RX-API-DMAC7.html)
KR (10) KR20200118228A (cg-RX-API-DMAC7.html)
CN (4) CN110613679A (cg-RX-API-DMAC7.html)
AR (2) AR086409A1 (cg-RX-API-DMAC7.html)
AU (11) AU2012257492A1 (cg-RX-API-DMAC7.html)
BR (2) BR112013029336B1 (cg-RX-API-DMAC7.html)
CA (3) CA2836405C (cg-RX-API-DMAC7.html)
DK (1) DK2714006T3 (cg-RX-API-DMAC7.html)
EA (1) EA201391701A1 (cg-RX-API-DMAC7.html)
ES (1) ES2859784T3 (cg-RX-API-DMAC7.html)
IL (2) IL229401A0 (cg-RX-API-DMAC7.html)
MX (4) MX363561B (cg-RX-API-DMAC7.html)
PL (1) PL2714006T3 (cg-RX-API-DMAC7.html)
WO (2) WO2012156820A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201309264B (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
KR20200118228A (ko) * 2011-05-15 2020-10-14 에이세러스 바이오파마 인크. 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
US8971800B2 (en) * 2011-05-31 2015-03-03 Qualcomm Incorporated Methods and apparatus for improving NFC activation and data exchange reporting mechanisms
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2014076569A2 (en) * 2012-11-14 2014-05-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
US20140171918A1 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
EP3054957B1 (en) * 2013-10-07 2019-10-02 Antares Pharma, Inc. Hematocrit modulation through needle assisted jet injection of testosterone
EP4062918A1 (en) * 2014-02-19 2022-09-28 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
WO2016123317A1 (en) * 2015-01-28 2016-08-04 Prometheon Pharma, Llc Topical formulations of growth factors
US10219894B2 (en) * 2015-06-29 2019-03-05 480 Biomedical, Inc. Implantable scaffolds for treatment of sinusitis
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR102015020878B1 (pt) * 2015-08-28 2019-08-27 F B M Ind Farmaceutica Ltda formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona.
AU2017206048B2 (en) * 2016-01-07 2023-04-13 Viramal Limited Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
MX2018012967A (es) 2016-04-25 2019-03-06 Koska Family Ltd Sistema de suministro medico.
WO2017208072A2 (en) * 2016-06-02 2017-12-07 Acerus Pharmaceutical Corporation Nasal cannabidiol compositions
SG11201810628XA (en) * 2016-06-03 2018-12-28 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
KR20190109452A (ko) 2017-01-20 2019-09-25 엠 이티 피 파마 아게 대기 오염 물질에의 노출 위험을 감소시키기 위한 비강 약학적 조성물
WO2018231027A1 (ko) * 2017-06-17 2018-12-20 엘지전자(주) 무선 통신 시스템에서 단말의 등록 방법 및 이를 위한 장치
EP3710086A4 (en) 2017-11-17 2021-11-17 Koska Family Limited SYSTEMS AND PROCESSES FOR FLUID DISPENSERS
JP7321096B2 (ja) * 2017-11-27 2023-08-04 あすか製薬株式会社 粉末経鼻投与製剤
SG11202007303YA (en) * 2018-02-02 2020-08-28 Aytu Bioscience Inc Methods of testosterone therapy
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
CN108771622B (zh) * 2018-07-11 2022-01-07 尹振图 一种自闭式针形滴嘴及眼药水瓶
CA3117842A1 (en) 2018-10-26 2020-04-30 Viramal Limited Mucoadhesive gel composition
ES2948955T3 (es) 2018-11-30 2023-09-22 Viramal Ltd Un método de preparación de un agente gelificante, el agente gelificante obtenido de este modo y el uso de dicho agente gelificante
US20200170962A1 (en) 2018-11-30 2020-06-04 F. Markus Leweke Nasal cannabidiol compositions
PH12021551396A1 (en) * 2018-12-14 2022-05-11 Acerus Biopharma Inc Active ester derivatives of testosterone, compositions and uses thereof
USD1052082S1 (en) 2020-06-01 2024-11-19 Koska Family Limited Sealed fluid container
CN112121049B (zh) * 2020-08-28 2022-02-01 嘉兴市第一医院 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用
EP4247332A1 (en) * 2020-11-19 2023-09-27 Acousia Therapeutics GmbH Non-aqueous gel composition
GB202307501D0 (en) * 2023-05-19 2023-07-05 Lawley Pharmaceuticals Pty Ltd Process for preparing dispensable testosterone cream

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
DE4214953C2 (de) 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
US5756071A (en) 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5576071A (en) 1994-11-08 1996-11-19 Micron Technology, Inc. Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds
JP2000514065A (ja) * 1997-07-03 2000-10-24 アルザ コーポレイション ドラッグデリバリーディバイスとその製造法
EP1510213B1 (en) * 1997-11-10 2008-12-31 Strakan International Limited Penetration enhancing and irritation reducing systems comprising testosterone
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
WO2005039531A1 (en) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10064950A1 (de) * 2000-12-23 2002-07-11 Impetus Ag Basel Thixotropes Nasenspray
EP1450739A4 (en) * 2001-10-12 2008-12-17 Cns Inc NASAL MOISTURIZING GEL AND APPLICATOR
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
DK1530965T3 (da) * 2003-11-11 2006-07-17 Mattern Udo Kontrolleret frigivelsesleveringssystem til nasal applikation
NZ555641A (en) * 2004-12-09 2010-10-29 Bayer Animal Health Gmbh Stabilisation of glucocorticoid esters with acids
EA019214B1 (ru) * 2005-06-03 2014-02-28 АКРУКС ДиДиЭс ПиТиУай ЭлТиДи Способ лечения или профилактики заболеваний, вызванных дефицитом андрогенов у взрослых мужчин
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
CN101099742A (zh) * 2006-07-06 2008-01-09 上海富海科申药业有限公司 能够减少皮肤刺激的睾酮凝胶制剂
PT2068825E (pt) * 2006-10-04 2011-02-11 M & P Patent Ag Sistema de administração de libertação controlada para aplicação nasal de neurotransmissores
CN101754764A (zh) * 2007-03-23 2010-06-23 优尼麦德药物股份有限公司 治疗小儿性腺机能减退的组合物和方法
WO2009037813A1 (ja) * 2007-09-20 2009-03-26 Shiseido Company, Ltd. 経皮吸収製剤
ES2628507T3 (es) * 2007-11-13 2017-08-03 Athenion Ag Esteroides C-19 para el tratamiento de la celulitis
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
KR20200118228A (ko) * 2011-05-15 2020-10-14 에이세러스 바이오파마 인크. 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도

Also Published As

Publication number Publication date
BR112013029336B1 (pt) 2021-11-30
JP2021001206A (ja) 2021-01-07
IL229401A0 (en) 2014-01-30
AU2019201618A1 (en) 2019-04-18
CN103796636A (zh) 2014-05-14
KR20190006194A (ko) 2019-01-17
CA2836405A1 (en) 2012-11-22
KR102088038B1 (ko) 2020-03-13
CN109481394A (zh) 2019-03-19
JP2020079257A (ja) 2020-05-28
JP6594924B2 (ja) 2019-10-23
CN103813784A (zh) 2014-05-21
KR20240162608A (ko) 2024-11-15
AU2019203400A1 (en) 2019-08-01
BR112013029332A2 (pt) 2021-06-01
AU2012257492A1 (en) 2013-12-19
KR20210135003A (ko) 2021-11-11
MX2020008599A (es) 2022-08-31
EP2709588A1 (en) 2014-03-26
KR102568894B1 (ko) 2023-08-21
JP2014513716A (ja) 2014-06-05
AR089553A1 (es) 2014-09-03
CN109481394B (zh) 2023-05-05
MX2013013388A (es) 2014-09-15
AU2020267162A1 (en) 2020-12-03
JP6152092B2 (ja) 2017-06-28
KR20190117803A (ko) 2019-10-16
WO2012156822A1 (en) 2012-11-22
PL2714006T4 (pl) 2021-08-16
KR20210029849A (ko) 2021-03-16
JP2014515038A (ja) 2014-06-26
AU2019203067A1 (en) 2019-05-23
KR20200028503A (ko) 2020-03-16
AU2012257490A1 (en) 2013-12-19
BR112013029336A2 (pt) 2020-08-11
AU2017203470A1 (en) 2017-06-22
KR20140045400A (ko) 2014-04-16
AU2020267162B2 (en) 2022-06-09
JP2022078222A (ja) 2022-05-24
MX395212B (es) 2025-03-21
CA2836398C (en) 2021-12-14
JP7017254B2 (ja) 2022-02-08
CA2836398A1 (en) 2012-11-22
AU2024216312A1 (en) 2024-10-24
CA3034552C (en) 2023-02-07
JP2018199701A (ja) 2018-12-20
WO2012156820A1 (en) 2012-11-22
MX363561B (es) 2019-03-27
AU2020210227A1 (en) 2020-08-20
WO2012156820A9 (en) 2014-02-20
JP2017160204A (ja) 2017-09-14
EP2714006A1 (en) 2014-04-09
AU2022202402A1 (en) 2022-05-12
AR086409A1 (es) 2013-12-11
CN110613679A (zh) 2019-12-27
CN103796636B (zh) 2019-04-05
JP2020073469A (ja) 2020-05-14
KR20200118228A (ko) 2020-10-14
MX374398B (es) 2025-03-06
JP2022105175A (ja) 2022-07-12
CA3034552A1 (en) 2012-11-22
EA201391701A1 (ru) 2014-04-30
PL2714006T3 (pl) 2021-08-16
MX2019003340A (es) 2019-07-04
CA2836405C (en) 2021-09-07
AU2017204182A1 (en) 2017-07-20
KR20140033408A (ko) 2014-03-18
EP2714006B1 (en) 2020-12-09
EP2709588B1 (en) 2021-08-25
EP3977982A1 (en) 2022-04-06
ZA201309265B (en) 2016-01-27
KR20230041081A (ko) 2023-03-23
MX2013013369A (es) 2014-10-17
ES2859784T3 (es) 2021-10-04
ZA201309264B (en) 2015-09-30
IL229400A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
DK2714006T3 (da) Intranasale bioadhæsive testosterongelformuleringer og anvendelse deraf til behandling af mandlig hypogonadisme
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK2774616T3 (da) Anvendelse af roseburia i behandling og forebyggelse af fedmerelaterede sygdomme
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2624567T3 (da) Blokinddelingsfremgangsmåde og afkodningsindretning
IL235858A0 (en) Devices and scaffolds for tissue repair
DK2609956T3 (da) Midlertidigt foldbart kateteraggregat og dertil hørende fremgangsmåde
DK2521221T4 (da) Høreanordning og fremgangsmåde
DK2872419T3 (da) Fordelingsbeholder og tilsvarende fremgangsmåde
DK2552434T3 (da) Peptider og anvendelse deraf
DK2600715T3 (da) Flydende ST-246-formuleringer og fremgangsmåder
LT2605789T (lt) Modifikuoti relaksino polipeptidai ir jų panaudojimas
DK3550836T3 (da) Fremgangsmåde og anordning til afkodning
DK3967868T3 (da) Væskeforstøver og fremgangsmåde
LT2895512T (lt) Žmogaus salelių amiloido polipeptido (hiapp) specifiniai antikūnai ir jų panaudojimas
PL2934093T3 (pl) Trwała transformacja populacji i sposób ochrony biologicznej z wykorzystaniem zasad haploinsuficjencji i poddominacji
DK2917231T3 (da) Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme
HUE13837694T1 (hu) Daptomicin készítmények és alkalmazásaik
DK2549995T3 (da) Brug af anatabin til behandling af inflammation og metoder til syntetisering af anatabin
IL234906A0 (en) Colchicine compositions, methods of production and methods of using them
PL2521445T3 (pl) Preparat i jego zastosowanie
DK2889365T3 (da) Fremgangsmåde til undersøgelse af mikroorganismer og indretning dertil
DK2943460T3 (da) 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf
DK3363437T3 (da) Aminoindanforbindelser og anvendelse deraf i behandling af smerte